2017 Press Releases

1/23/2018

Aachen, Germany, October 30, 2017 – The Grünenthal Group announced today that the company renewed its syndicated loan facility on October 20, 2017. For the next five years, the company can access € 400 million of available loan granted by a bank consortium. In the course of the renewal the Grünenthal Group was able to achieve significantly improved terms and conditions, including lower loan margins. This syndicated loan facility is an essential pillar of the company’s financing strategy, which also includes the recently issued promissory note (Schuldscheindarlehen).

12/4/2017

Aachen, Germany, December 4, 2017 – The Grünenthal Group announced today that Nucynta^® (tapentadol) will be commercialized in the U.S. territory by Collegium Pharmaceutical, Inc., instead of Depomed, Inc., from 2018 onwards.

11/16/2017

Aachen, Germany, November 16, 2017 – Many patients who suffer strong or persistent pain receive inadequate relief from therapy. Improving pharmacotherapy and management for refractory pain is a so enormously complex problem that only concerted approaches which link together groups with different relevant expertise are likely to have success in discovering and developing novel and effective analgesics.

9/7/2017

Copenhagen, 7 September, 2017. Significant unmet medical needs in the field of pain in Europe have made pain research more relevant than ever. On the occasion of the congress of the European Pain Federation EFIC^®, young scientists from across Europe presented the results of their pain research projects, which focus on novel ideas with the potential for achieving major advances in pain Management.

9/1/2017

Aachen, Germany, September 1, 2017. The Grünenthal Group today announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO). Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca.

8/28/2017

Aachen, Germany, 28. August 2017. Grünenthal GmbH issued a promissory note at the end of July 2017. The transaction was announced with a volume of € 150 million. Due to the strong interest of investors and the subsequent oversubscription, the initial transaction volume has been well exceeded and increased to € 300 million. Grünenthal diversifies its lenders and increases its lender base with the promissory note.

7/5/2017

The new research project NGN-PET was launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. The NGN-PET consortium unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia.

6/13/2017

Valletta, June 13, 2017 – During his speech at the Societal Impact of Pain symposium in Valletta, Malta, Gabriel Baertschi, CEO of Grünenthal and board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) emphasized the increased necessity of addressing the impact of pain on society.

6/7/2017

Aachen, June 07, 2017 - The Grünenthal Group today announced that it has entered into an agreement with AstraZeneca for the global rights to Zomig® (Zolmitriptan) excluding Japan. Zomig® is indicated for the acute treatment of migraines and cluster headaches. The transaction is expected to be completed before the end of the second quarter of 2017, subject to regulatory clearances.

5/29/2017

Aachen, Germany, May 29, 2017. The Grünenthal Group, an R&D-driven, privately held international pharmaceutical company with headquarters in Aachen Germany, announced today that it has received the renowned Red Dot Product Design Award in the category life sciences and medicine for an innovative system for post-operative pain management. The “Red Dot” is given for good design and innovation. Patients are able to self-administer a pain drug using this system. The product has been available to patients in Western Europe since the first half of 2016.

5/23/2017

Brussels/Aachen, 23 May, 2017. The European Pain Federation EFIC® in cooperation with the pharmaceutical company Grünenthal announced that six young research scientists in the field of pain will be awarded an EFIC-GRÜNENTHAL Grant (E-G-G). This biennial grant, totalling € 200,000, supports up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects.

5/10/2017

Aachen, Germany – Wednesday May 10, 2017. Grünenthal, a worldwide leader in Pain, announced today that it has opened a new Innovation Hub in the Greater Boston area. Through this Innovation Hub, Grünenthal aims to identify promising projects in pain, inflammation, orphan diseases, and devices & technologies from the large number of projects in late discovery and early development in the region. .

5/9/2017

Aachen, Germany, May 09, 2017. The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017.

5/3/2017

May 3, 2017 - Mountain View, Calif., and Aachen, Germany – Today 23andMe, Inc. and Grünenthal announced a joint study to better understand how genes influence pain. Together, they seek to enroll 20,000 participants from the U.S. The study will be one of the largest of its kind to combine data on genetics and response to pain, including a pain tolerance experiment. 23andMe is a leading personal genetics company, and the Grünenthal Group is an entrepreneurial, science-based German pharmaceutical company specializing in pain, gout and inflammation.

4/7/2017

Aachen, Germany, April 7, 2017. The Grünenthal Group today announced the acquisition of Adhesys Medical GmbH and its US-based affiliate Adhesys Medical Inc., a Medical Device Startup company focused on the development of adhesives used in surgery. Through this acquisition, Grünenthal has obtained the worldwide development and commercialization rights of an innovative pipeline of surgical sealants together with the underlying technology platform. The first innovative topical skin adhesive is expected to receive European-wide CE Marketing Certification within the next 12 months.

3/29/2017

Hamburg and Aachen / DE, 29. March 2017 - Logistics provider Kuehne + Nagel and pharmaceutical research company Grünenthal agree global partnership for land, air and seafreight. Kuehne + Nagel is supporting the Grünenthal Group with the reorganisation of the world-wide transportation network for highly sensitive pharmaceutical products.

1/12/2017

Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America.